4DMedical\u2019s unique XV Technology\u2122 has propelled a team of medical researchers to a 2023 Eureka Prize win, announced at a ceremony in Sydney last night. The Australian Museum Eureka Prizes are the country\u2019s most comprehensive national science awards, honouring excellence across the areas of research and innovation, leadership, science engagement and school science.<\/p>\n\n\n\n
The Cystic Fibrosis Lung Health Imaging project team led by Associate Professor David Parsons comprises researchers from the University of Adelaide, the Women\u2019s & Children\u2019s Hospital (Adelaide), Monash University and technology innovator 4DMedical. Professor Andreas Fouras, inventor of XV Technology and founder of 4DMedical was one the team awarded the prestigious Aspire Scholarship Eureka Prize for Excellence in Interdisciplinary Scientific Research.<\/p>\n\n\n\n
Treating children with Cystic Fibrosis requires physicians to know the location and extent of abnormal airflow. 4DMedical\u2019s novel medical imaging capability, XV Technology, enabled the multidisciplinary project team to form a basis for detecting, treating and monitoring Cystic Fibrosis and other lung diseases.<\/p>\n\n\n\n
\u201cWe are so pleased that the interdisciplinary research work undertaken by our team across engineering, physics, X-ray imaging, image analysis, lung medicine, and cystic fibrosis, has been recognised by the Eureka judges.\u201d said Associate Professor Parsons.<\/p>\n\n\n\n
\u201cXV lung imaging holds real potential for detecting the earliest beginnings of lung disease in very young children with Cystic Fibrosis, something that has not been possible with the existing lung health tests,\u201d added Associate Professor Martin Donnelley of the Robertson Research Institute. \u201cXV can show exactly where in the lung disease is beginning, it means prevention of disease can become a reality by precisely targeting treatment to just those areas affected before disease can establish.\u201d<\/p>\n\n\n\n
Both experts are so committed to the successful outcomes of this new technology that they have personally invested in 4DMedical, the company that has translated XV imaging into a clinical tool.<\/p>\n\n\n\n